acquired
Stage
2004
Founded
1
Investors
About
Calliditas Therapeutics is a biopharmaceutical company focused on developing treatments for rare diseases, particularly in renal and hepatic indications. The company commercializes TARPEYO® (budesonide) for IgA nephropathy and has a pipeline including setanaxib for primary biliary cholangitis and solid tumors.
Explore Calliditas's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.